Skip to main content

Mammography Plus Ultrasound Superior to Mammography With AI for Dense Breasts

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

TUESDAY, Aug. 1, 2023 -- Mammography with supplementary ultrasound has higher accuracy and a lower recall rate than mammography with artificial intelligence (AI) or mammography with ultrasound and AI, according to a study published online July 26 in the American Journal of Roentgenology.

Si Eun Lee, M.D., Ph.D., from the Yonsei University College of Medicine in Yongin, South Korea, and colleagues compared the performance characteristics of screening mammography alone, standalone AI, ultrasound alone, and mammography combined with AI and/or ultrasound in 1,325 women with dense breasts who underwent screening mammography and supplementary breast ultrasound within a one-month interval.

The researchers found that 12 cancers were diagnosed (six invasive ductal carcinoma and six ductal carcinoma in situ). Per 1,000 patients, the cancer detection rate was 6.0, 6.8, and 6.0 for mammography, standalone AI, and ultrasound, respectively, with corresponding recall rates of 4.4, 11.9, and 9.2 percent; sensitivity of 96.2, 88.7, and 91.3 percent; specificity of 96.2, 88.7, and 91.3 percent; and accuracy of 95.9, 88.5, and 91.1 percent. Cancer detection rates were 7.5, 9.1, and 9.1 for mammography with AI, mammography with ultrasound, and mammography with both AI and ultrasound, respectively, with corresponding recall rates of 14.9, 11.7, and 21.4 percent, and sensitivity, specificity, and accuracy of 83.3, 100.0, and 100.0 percent; 85.8, 89.1, and 79.4 percent; and 85.7, 89.2, and 79.5 percent, respectively.

"The findings fail to show a benefit of AI when performed in addition to supplementary ultrasound in patients with dense breasts undergoing screening mammography," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2023

Read this next

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care

TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.